Module

Update on Lymphoma Management: Chronic Lymphocytic Leukemia

Source: Lymphoma Annual Update 2005

Update on Lymphoma Management: Chronic Lymphocytic Leukemia


Program Director: Julie M. Vose, MD

Faculty:

  • Susan M. O'Brien, MD

CME CREDIT INFORMATION

Release Date: 09/02/05

Expiration Date: 09/01/06


Physicians: maximum of 1 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe novel treatments being evaluated in patients with CLL.

  • Review data describing treatment of chronic lymphocytic leukemia (CLL).

  • Recount the prognostic indicators of CLL.


Content includes:

  • VHGene Mutation Status and ZAP-70 Expression as Prognostic Indicators
  • Genomic Aberrations in CLL
  • Combination Chemotherapy for CLL
  • Chemotherapy Plus Rituximab
  • Alemtuzumab for Refractory CLL
  • Alemtuzumab for Eliminating MRD
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grants provided by:

Educational grants support only the CME-certified components of this program.